Alvotech FDA Approval Clears Path To Challenge Humira
Simlandi Is First US Interchangeable Citrate-Free High-Concentration Adalimumab Biosimilar
Alvotech and US marketing partner Teva can now launch “imminently” their long-planned rival to Humira, with the firms believing that the Simlandi biosimilar will stand out from the crowd of other adalimumab challengers thanks to a unique combination of product attributes.
